The results appeared to suggest that GHRP-2 may lead to a rise in circulating IGF-I levels, potentially ranging between 1.2 to 1.6 times the baseline levels
62,98 Clinical Studies in PD In a proof of concept open label clinical trial, 45 patients with moderate PD, on convential PD therapy, were randomly assigned to receive subcutaneous exenatide injection (in the form Byetta : 5 g administered subcutaneously twice daily for the first month followed by a 10 g dose twice daily thereafter) or were controls for 12 mo, followed by a 2-mo washout period to allow comparison between the exenatide and control groups in the absence of drug (to potentially avoid any potential symptomatic effects of exenatide)
Koehler RT, Villar HO, Bauer KE, Higgins DL
Lyophilized: Hold the dry blend vial at 20 C (4 F) in dry, dark conditions and limit moisture exposure
LA classification: If an EGD is performed, record the LA Grade of esophagitis (AD) to support K21.00/K21.01